PURE — Pure Biosciences Income Statement
0.000.00%
Last trade - 00:00- $5.91m
- $10.81m
- $2.20m
- 25
- 30
- 13
- 10
Annual income statement for Pure Biosciences, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | 2025 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.93 | 1.85 | 1.88 | 1.96 | 2.2 |
| Cost of Revenue | |||||
| Gross Profit | 2.08 | 1 | 0.971 | 1.15 | 1.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.24 | 5.34 | 5.82 | 5.15 | 4.47 |
| Operating Profit | -2.31 | -3.48 | -3.94 | -3.19 | -2.27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.32 | -3.49 | -3.96 | -3.35 | -2.4 |
| Net Income After Taxes | -2.32 | -3.49 | -3.96 | -3.35 | -2.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.32 | -3.49 | -3.96 | -3.35 | -2.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.32 | -3.49 | -3.96 | -3.35 | -2.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.027 | -0.039 | -0.033 | -0.029 | -0.021 |